Why Flu Season Is Starting Early in 2026: The Mutation Behind the Surge

Influenza indicators in the United States began climbing earlier than usual this autumn. The Centers for Disease Control and Prevention (CDC) reported that 5.0% of clinical laboratory specimens tested positive for flu in the week ending October 10, 2026, up from 3.9% the previous week, with the agency describing early-season activity as higher than typically observed for this time of year, though still within the range of expected seasonal variation.

Where activity is highest

According to the CDC's Week 40 FluView report, the highest influenza activity is occurring on the West Coast, specifically HHS Regions 9 and 10, which cover states including California, Washington, Arizona, Hawaii and Nevada. A separate CDC-based analysis reported by Medical Daily found flu activity growing or likely growing in 46 states as of October 14, with HHS Region 9 (Arizona, California, Hawaii and Nevada) recording roughly 9.5% test positivity, the highest in the country. The CDC also began rolling out a new local forecasting tool this month designed to flag state-level outbreak peaks two to three weeks earlier than previous methods, per the same report.

The H3N2 subclade K mutation

Part of the explanation offered by researchers involves a mutated influenza A(H3N2) virus known as subclade K, formally designated J.2.4.1. According to a study on England's autumn 2025 season published via the National Center for Biotechnology Information (PMC), subclade K carries a cluster of mutations — including T135K, K189R, K2N, S144N, N158D, I160K, Q173R, T328A and S378N — that caused it to drift antigenically from earlier H3N2 vaccine strains. The same study found that subclade K's emergence coincided with England's earliest inter-pandemic flu season start since 2003–04.

Discover Magazine reported that subclade K was first characterized by the CDC from samples collected in August 2025 and has since circulated widely. The outlet cited infectious disease specialist Demetre Daskalakis, a former CDC official, noting that influenza causes tens of thousands of hospitalizations and deaths every year, and cited experts who suggested the mutated strain's altered surface antigens may make it harder for the immune system to recognize, a possible factor in the unusually early rise in cases. Discover Magazine reported continuous increases since early September 2026 in California, Washington, Hawaii and Alaska.

The national picture is more mixed by subtype. In the CDC's own Week 40 sample of 300 characterized viruses, 292 were influenza A and 8 were influenza B; among the 251 subtyped influenza A viruses, 242 (96.4%) were A(H1N1)pdm09 and only 9 (3.6%) were A(H3N2). The CDC noted that A(H1N1)pdm09 has dominated reported influenza A viruses since late May, accounting for 79.3% of them. This means that while subclade K's immune-evading mutations are cited as a contributing factor in reports on the season's early start, the strain circulating most heavily in CDC's most recent national lab data is a different subtype, H1N1pdm09 — a distinction that can vary by week and region.

Does the vaccine still work?

The PMC-published UKHSA analysis found that despite subclade K showing more than a 32-fold reduction in antibody reactivity against egg-propagated vaccine strains in laboratory tests, estimated vaccine effectiveness against emergency department attendance and hospital admission for influenza A overall was 72–75% in children and adolescents and 32–39% in adults during the period when subclade K predominated. Because subtyping of samples was incomplete, the study could not produce precise effectiveness estimates specific to subclade K or H3N2 alone; a preliminary estimate of around 60% against H3N2 specifically was calculated for adults aged 18–64, though with wide, overlapping confidence intervals. The researchers concluded that "vaccination remains effective against clinical disease caused by influenza A(H3N2) viruses," even with reduced antibody matching in laboratory tests. Discover Magazine reported that the 2026–2027 vaccines were updated to target subclade K specifically.

Vaccination rates remain below target

CDC's FluVaxView data for the 2025–2026 season show overall vaccination coverage among people aged 6 months and older at 43.8%, well below the Healthy People 2030 target of 70%. Coverage varies widely by state and age group.

CDC data show state-level coverage for children ranging from 30.9% in Mississippi to 74.6% in Connecticut, and for adults from 29.3% in Idaho to 57.6% in Massachusetts. The agency's report described the slight uptick in child coverage as the first increase since before the COVID-19 pandemic, though both child and adult rates remain below historical pre-pandemic levels.

On hospitalizations, CDC's FluSurv-NET network recorded 256 flu hospitalizations in Week 40, a rate of 0.7 per 100,000 population (estimated at 1.2 after adjusting for reporting lags), with the highest rate among adults 65 and older at 2.3 per 100,000.